Key Highlights
- Moderna (NASDAQ:MRNA) rose 5.67% to USD 208.16 in the October 9, 2026 session, a gain of USD 11.16, with no company announcement found, ahead of the October 24 ESMO presentation of its melanoma Vaccine trial.
- Novavax (NASDAQ:NVAX) rose 8.99% to USD 12.00 in the October 9, 2026 session on Volume of 7.623 million shares, and a search found no company announcement dated October 8 or October 9 to explain the gain.
- Teva (NYSE:TEVA) rose 5.68% to USD 41.48 in the October 9, 2026 session after a company release at 7:00 a.m. ET announced FDA approval of Weltruza, a once monthly extended-release injectable olanzapine for adults with schizophrenia.
- Only Teva (NYSE:TEVA) had a same day catalyst. Two peers rose without announcements, so their gains rest on older news, sector flows and expectations rather than fresh company disclosures, which makes them harder to explain and easier to reverse.
Moderna (NASDAQ:MRNA): Expectations Before the Madrid Data
Moderna (NASDAQ:MRNA) rose 5.67% to USD 208.16 in the October 9, 2026 session, a gain of USD 11.16 from a prior close near USD 197.00 (simple arithmetic on two published numbers), on about 13.0 million shares. No company release, filing or analyst action dated October 8 or 9 was found, so the specific trigger is unknown. The most recent verified catalysts are older: on August 19 Moderna and Merck said their Phase 3 trial of intismeran autogene plus Keytruda in melanoma met its primary endpoint, and on September 21 the data were reported as chosen for an ESMO Presidential Symposium slot. The study, called INTerpath-001, tests the personalized mRNA vaccine plus pembrolizumab against pembrolizumab alone in patients whose melanoma was surgically removed. Moderna shares jumped more than 170% on August 19, as reported, and the companies did not release a hazard ratio, so investors await the full dataset. William Blair upgraded the stock, while Evercore ISI said the valuation already prices in more conviction than the disclosed data support, as reported. The 52-week gain is about 634.25%, so any weak spot in the data could trigger a steep selloff. Watch the presentation on October 24 and the investor webcast that same day, along with any safety or durability detail in the slides. Moderna (NASDAQ:MRNA) also faces vaccine Demand pressure and heavy spending.
Novavax (NASDAQ:NVAX): A Gain Without an Announcement
Novavax (NASDAQ:NVAX) rose 8.99%, or USD 0.99, to USD 12.00 in the October 9, 2026 session on volume of 7.623 million shares. A search of company releases and published reports found no announcement dated October 8 or October 9, so there is no company announcement found to name as the catalyst. The stock is volatile, with a reported Beta above 2, and moves of this size can come from sector flows, vaccine headlines, Options activity or short covering, none of which can be confirmed. The most important verified update is the second quarter report released on August 6, 2026. Total Revenue was USD 57 million, down 76% from USD 239 million a year earlier, when it included a USD 175 million approval milestone. Product sales were USD 19 million, up 76%. Net loss was USD 53 million, or USD 0.32 per share. The company raised 2026 adjusted total revenue guidance to USD 235 million to USD 275 million. Much of the upside rests on Sanofi, including a USD 125 million milestone payable when a Phase 3 combination COVID-19 and influenza trial starts, and regulators and Sanofi control that timing. Over 52 weeks the stock is up about 32.17%, so Novavax (NASDAQ:NVAX) has already run well. Cash, equivalents and restricted cash were USD 724 million at the end of June, down from USD 751 million at year end.
Teva (NYSE:TEVA): An Approval That Met Guidance
Teva (NYSE:TEVA) rose 5.68%, or USD 2.23, to USD 41.48 in the October 9, 2026 session on volume of 6.176 million shares. The catalyst was a company release at 7:00 a.m. ET announcing FDA approval of Weltruza, an extended-release injectable olanzapine given subcutaneously once a month to adults with schizophrenia. Management had guided on its July 29 second quarter call to an FDA decision and launch in the fourth quarter of 2026, so the timing met expectations. Approval was based on the SOLARIS trial, an 8-week placebo-controlled study of 675 patients followed by a 48-week period. The company said Weltruza needs no loading doses, oral supplementation or post-injection monitoring, which could make it easier to prescribe than a competing injection that requires observation. Teva reported second quarter revenue of USD 4.14 billion on July 29, as reported, but it disclosed no sales forecast for Weltruza. The label includes a boxed warning of increased mortality in elderly patients with dementia-related psychosis, and weight gain and metabolic effects are common with olanzapine. The company carried net Debt of USD 12.9 billion at the end of the second quarter, as reported, and the stock is up 95.96% over 52 weeks, so expectations are high. Watch the US launch in the coming weeks, payer coverage and the European review that began in May 2026.
Where Things Stand
Teva (NYSE:TEVA) rose on an FDA approval. Moderna (NASDAQ:MRNA) and Novavax rose without announcements found, so two of the three gains lack a stated cause. Novavax (NASDAQ:NVAX) is the more volatile of the pair. Compare the three on verifiability: one has a dated company release, one has an older trial result with an upcoming presentation, and one has neither. Watch the Weltruza launch and payer coverage, the October 24 ESMO presentation, any Sanofi milestone news for Novavax and each company's next quarterly report, whose dates were not verified. Large moves in volatile biotech names can reverse in the next session, so one day is a weak guide.






Please wait processing your request...